Scinai Completes Recipharm Israel Acquisition, Forms Strategic Commercial Collaboration

summarizeSummary

Scinai Immunotherapeutics announced the completion of its acquisition of Recipharm Israel Ltd. and a strategic commercial collaboration with Recipharm, significantly expanding its CDMO capabilities and market reach.

check_boxKey Events

• Acquisition of Recipharm Israel Ltd. Completed

  Scinai acquired 100% of Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, providing early chemistry development and small-scale API manufacturing for clinical programs. This acquisition expands Scinai's manufacturing footprint and capabilities.

• Strategic Commercial Collaboration with Recipharm Established

  Scinai and Recipharm entered a long-term agreement where Scinai will be a preferred partner for early-stage development, and Recipharm for late-stage clinical and commercial manufacturing. The collaboration includes mutual client referrals and shared economics as programs advance.

• Expanded CDMO Offering and Market Positioning

  The transactions significantly strengthen Scinai's CDMO platform, creating a differentiated, end-to-end development and manufacturing offering. This allows Scinai to support clients from early development through commercialization, addressing a common industry challenge for smaller CDMOs.

auto_awesomeAnalysis

Scinai Immunotherapeutics has significantly expanded its contract development and manufacturing organization (CDMO) capabilities and market reach through the acquisition of Recipharm Israel Ltd. and a strategic commercial collaboration with Recipharm. This move creates a differentiated, end-to-end offering for clients, spanning early development through late-stage clinical and commercial supply. The collaboration is designed to streamline client transitions to Recipharm's global network and allows Scinai to participate economically in the long-term success of client programs, enhancing its competitive positioning in the CDMO market.